Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19 | COVID-19 Treatment Guidelines

The doses and indications listed below come from the FDA product information. Please see Therapeutic Management of Hospitalized Adults With COVID-19 for the Panel’s recommendations on when to use RDV.

For Hospitalized Adults and Children (Aged ≥12 Years and Weighing ≥40 kg)

For Patients Who Are Not Mechanically Ventilated and/or on ECMO:

For Mechanically Ventilated Patients and/or Patients on ECMO:

Suggested Dose in EUAb for Hospitalized Children

For Patients Weighing 3.5 kg to <40 kg:

For Patients Aged <12 Years and Weighing ≥40 kg:

Adults: Adults:
https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/